← Back to Screener
Tilray Brands, Inc. Common Stock (TLRY)
Price$7.15
Favorite Metrics
Price vs S&P 500 (26W)-68.86%
Price vs S&P 500 (4W)0.97%
Market Capitalization$833.32M
All Metrics
Book Value / Share (Quarterly)$13.36
P/TBV (Annual)0.29x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)9.34%
Cash Flow / Share (Quarterly)$-0.63
Price vs S&P 500 (YTD)-28.17%
Gross Margin (TTM)27.68%
Net Profit Margin (TTM)-156.67%
EPS (TTM)$-1.95
10-Day Avg Trading Volume2.80M
EPS Excl Extra (TTM)$-1.95
Revenue Growth (5Y)31.30%
EPS (Annual)$-2.46
ROI (Annual)-120.53%
Gross Margin (Annual)29.29%
Net Profit Margin (5Y Avg)-135.29%
Cash / Share (Quarterly)$1.89
Revenue Growth QoQ (YoY)11.28%
ROA (Last FY)-105.42%
Revenue Growth TTM (YoY)3.82%
EBITD / Share (TTM)$-4.46
ROE (5Y Avg)-42.94%
Operating Margin (TTM)-173.67%
Cash Flow / Share (Annual)$-0.12
P/B Ratio0.54x
P/B Ratio (Quarterly)0.57x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1.08x
Net Interest Coverage (TTM)-47.45x
ROA (TTM)-64.57%
EV / EBITDA (TTM)7.54x
EPS Incl Extra (Annual)$-2.46
Current Ratio (Annual)2.46x
Quick Ratio (Quarterly)1.50x
3-Month Avg Trading Volume7.05M
52-Week Price Return44.12%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$13.16
P/S Ratio (Annual)1.01x
Asset Turnover (Annual)0.40x
52-Week High$23.20
Operating Margin (5Y Avg)-128.28%
EPS Excl Extra (Annual)$-2.46
CapEx CAGR (5Y)-5.91%
Tangible BV CAGR (5Y)51.38%
26-Week Price Return-60.12%
Quick Ratio (Annual)1.37x
13-Week Price Return-30.71%
Total Debt / Equity (Annual)0.20x
Current Ratio (Quarterly)2.79x
Enterprise Value$923.128
Revenue / Share Growth (5Y)-11.19%
Asset Turnover (TTM)0.41x
Book Value / Share Growth (5Y)-9.59%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.22x
Pretax Margin (Annual)-280.33%
Cash / Share (Annual)$0.24
3-Month Return Std Dev57.26%
Gross Margin (5Y Avg)24.73%
Net Income / Employee (TTM)$-0
ROE (Last FY)-144.68%
Net Interest Coverage (Annual)-10.53x
EPS Basic Excl Extra (Annual)$-2.46
P/FCF (TTM)80.25x
Receivables Turnover (TTM)7.74x
Total Debt / Equity (Quarterly)0.19x
EPS Incl Extra (TTM)$-1.95
Receivables Turnover (Annual)7.36x
ROI (TTM)-72.87%
P/S Ratio (TTM)0.97x
Pretax Margin (5Y Avg)-136.10%
Revenue / Share (Annual)$0.92
Tangible BV / Share (Annual)$1.40
Price vs S&P 500 (52W)9.02%
Year-to-Date Return-24.03%
5-Day Price Return2.08%
EPS Normalized (Annual)$-2.46
ROA (5Y Avg)-31.96%
Net Profit Margin (Annual)-266.25%
Month-to-Date Return6.03%
Cash Flow / Share (TTM)$-2.01
EBITD / Share (Annual)$-2.43
Operating Margin (Annual)-277.93%
LT Debt / Equity (Annual)0.16x
ROI (5Y Avg)-36.12%
LT Debt / Equity (Quarterly)0.14x
EPS Basic Excl Extra (TTM)$-1.95
P/TBV (Quarterly)0.58x
P/B Ratio (Annual)0.29x
Inventory Turnover (TTM)2.23x
Pretax Margin (TTM)-169.76%
Book Value / Share (Annual)$1.43
Price vs S&P 500 (13W)-33.57%
Beta2.06x
Revenue / Share (TTM)$7.62
ROE (TTM)-86.90%
52-Week Low$3.51
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.56
3.53
3.53
3.59
Industry Peers — Pharmaceutical Preparations(15)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TLRYTilray Brands, Inc. Common Stock | 0.97x | 3.82% | 27.68% | — | $7.15 |
CRONCronos Group Inc. Common Share | 6.99x | 24.63% | 42.81% | -49.98% | $2.76 |
CGCCanopy Growth Corporation Common Shares | 2.55x | 0.59% | 26.56% | — | $1.20 |
NAGENiagen Bioscience, Inc. Common Stock | 3.01x | 29.95% | 64.28% | — | $4.87 |
USNAUSANA Health Sciences Inc | 0.41x | 5.88% | 78.29% | -37.04% | $20.64 |
SNDLSundial Growers Inc. Common Shares | 0.58x | 2.82% | 27.33% | — | $1.54 |
MDWDMediWound Ltd. | 13.35x | -16.14% | 19.19% | — | $17.35 |
ACBAurora Cannabis Inc. Common Shares | 0.77x | 16.54% | 1.35% | — | $3.72 |
BTMDBiote Corp. Class A Common Stock | 0.46x | -2.52% | 71.46% | -26.84% | $2.24 |
FTLFFitLife Brands, Inc. Common Stock | 1.29x | 1.34% | 37.58% | -20.04% | $8.99 |
NAIINatural Alternatives International Inc. | 0.13x | 10.92% | 9.06% | — | $2.76 |
About
Tilray is a Canadian cannabis producer cultivating and distributing medical and recreational cannabis products. The company generates revenue primarily from the Canadian market and international medical cannabis exports, with U.S. operations concentrated in alcohol.